Edwards Plans $76 Million Expansion Of Singapore Heart-Valve Facility
This article was originally published in PharmAsia News
Edwards Lifesciences said it is expanding a manufacturing facility In Singapore to produce tissue for artificial heart valves, increasing its investment in the country to.$76 million over the past eight years.
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
Smiths Medical is increasing paraPAC ventilator production from hundreds to thousands a month to fulfill 10,000 units as part of the Ventilator Challenge UK consortium.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.